Logo

Upstate Partners with CXR Biosciences to Develop Drug-Screening Tests

Jun 22, 2005

NEW YORK, June 22 (GenomeWeb News) - A Serologicals subsidiary and CXR Biosciences plan to co-develop a series of in vitro tests to aid in the early-stage drug-discovery process.

 

The subsidiary, Upstate Group, will partner with the Dundee, Scotland-based CXR to develop the drug toxicity and metabolism screens to profile compounds in various cell-based and in vitro assays.

Breaking News
The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.